Iovance Biotherapeutics (NASDAQ: IOVA) is a clinical-stage biopharmaceutical company focused on developing and commercializing tumor-infiltrating lymphocyte (TIL) cell therapies for cancer patients. The company generates revenue through the sale of its FDA-approved TIL therapy, with its commercial product targeting solid tumor cancers. The 10-K filed 2026-02-24 references ongoing Phase 2 and Phase 3 clinical trials and interactions with the FDA regarding product candidates, indicating the company operates in an early commercial stage with pipeline assets still in development. The filing excerpts do not provide specific revenue figures, segment breakdowns, headquarters details, founding year, CEO tenure, or named competitors, so those details are omitted. Iovance trades on the Nasdaq Global Market under the ticker IOVA.

Revenue model

The filing excerpts do not provide sufficient detail to characterize the revenue model with specific figures or pricing structure.

Products and services

TIL-based cell therapies for solid tumor cancers; ongoing Phase 2 and Phase 3 clinical trials for additional product candidates, as referenced in the 10-K filed 2026-02-24.

Customers and end markets

The filing excerpts do not identify specific customers, customer concentration, or end market detail beyond the oncology indication for solid tumors.

Value-chain role

Biopharmaceutical developer and commercial-stage manufacturer of cell-based cancer therapies.

Geographic exposure

The filing excerpts do not specify geographic revenue mix or operational footprint.

Source: SEC 10-K, filed 2026-02-24

Industry: Biological Products, (No Diagnostic Substances) Peers: Agios Pharmaceuticals Inc Allogene Therapeutics Inc Travere Therapeutics Inc Ironwood Pharmaceuticals Inc Myriad Genetics Inc Novavax Inc Revolution Medicines Inc Vaxcyte Inc Xencor Inc